Society for Translational Medicine Expert Consensus on the Selection of Surgical Approaches in the Management of Thoracic Esophageal Carcinoma.
Yousheng Mao,Zhentao Yu,Bin You,Wentao Fang,Brian Badgwell,Mark F Berry,DuyKhanh P Ceppa,Chun Chen,Haiquan Chen,Miguel A Cuesta,Xavier Benoit D'Journo,Guy D Eslick,Jianhua Fu,Xiangning Fu,Shugeng Gao,Jianxing He,Jie He,Yunchao Huang,Gening Jiang,Zhongmin Jiang,Jae Y Kim,Danqing Li,Hui Li,Shanqing Li,Deruo Liu,Lunxu Liu,Yongyu Liu,Xiaofei Li,Yin Li,Weimin Mao,Daniela Molena,Christopher R Morse,Nuria M Novoa,Lijie Tan,Qunyou Tan,Alper Toker,Ti Tong,Qun Wang,Benny Weksler,Lin Xu,Shidong Xu,Tiansheng Yan,Lanjun Zhang,Xingyi Zhang,Xun Zhang,Zhu Zhang,Xiuyi Zhi,Qinghua Zhou
DOI: https://doi.org/10.21037/jtd.2018.12.07
2019-01-01
Journal of Thoracic Disease
Abstract:Esophageal cancer (EC) is a highly prevalent malignancy in China. According to the data released by National Cancer Registry Center of China in 2015, the prevalence of EC was 21.17/100,000 in China in 2012, ranking fifth among all malignancies; the mortality rate was 15.58/100,000, ranking fourth. It is expected that there will be 477,900 new EC cases nationwide in 2015, whereas 375,000 people will die from EC (1,2). Worldwide, EC is the 8 th most common malignancy, with 416,000 new cases in 2012 (3). At present, EC treatment is based on multidisciplinary treatment, but surgery remains the most effective therapy in optimizing long-term prognosis in patients without metastatic disease. The ideal surgical approach is a matter of debate.